Research article summary (published 30 Aug 2004):

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Full Abstract

This article discusses platelet active drugs as part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. New data on antiplatelet agents include the following: (1) the role of aspirin in primary prevention has been the subject of recommendations based on the assessment of cardiovascular risk; (2) an increasing number of reports suggest a substantial interindividual variability in the response to antiplatelet agents, and various phenomena of "resistance" to the antiplatelet effects of aspirin and clopidogrel; (3) the benefit/risk profile of currently available glycoprotein IIb/IIIa antagonists is substantially uncertain for patients with acute coronary syndromes who are not routinely scheduled for early revascularization; (4) there is an expanding role for the combination of aspirin and clopidogrel in the long-term management of high-risk patients; and (5) the cardiovascular effects of selective and nonselective cyclooxygenase-2 inhibitors have been the subject of increasing attention.

Author information

Author/s: Patrono, Carlo (C); Coller, Barry (B); FitzGerald, Garret A (GA); Hirsh, Jack (J); Roth, Gerald (G);

Affiliation: University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy. cpatrono(-atsign-)unich.it

Journal and publication information

Publication Type: Comparative Study; Journal Article

Journal: Chest (Chest), published in United States. (Language: eng)

Reference: 2004-Sep; vol 126 (issue 3 Suppl) : pp 234S-264S

Dates: Created 2004/09/22; Completed 2004/10/26; Revised 2007/11/15;

PMID: 15383474, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Administration, Oral Aspirin - administration & dosage; adverse effects; pharmacokinetics Coronary Thrombosis - blood; drug therapy Evidence-Based Medicine Humans Myocardial Revascularization Platelet Aggregation Inhibitors - administration & dosage; adverse effects; pharmacokinetics

Platelet Aggregation Inhibitors - administration & dosage; adverse effects; pharmacokinetics Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Randomized Controlled Trials as Topic Risk Factors Thromboembolism - blood; drug therapy Ticlopidine - administration & dosage; adverse effects; analogs & derivatives; pharmacokinetics Treatment Outcome

Associated Chemicals: Platelet Aggregation Inhibitors (0) ; Platelet Glycoprotein GPIIb-IIIa Complex (0) ; Aspirin (50-78-2) ; Ticlopidine (55142-85-3) ; clopidogrel (90055-48-4)

Related articles

These are the highest related articles currently in the database:

• Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. 30 Jan 2001
• Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? 30 Jan 2006
• Comment: Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? 31 Aug 2008
• Complications of oral antiplatelet medications. 30 Aug 2001
• Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. 30 Jul 2006
• Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. 30 Dec 1999
• [Must platelet aggregation inhibitors be discontinued before surgery?] 4 Feb 2004
• [The CREDO study has obvious shortages. More belief, less knowledge] 7 Oct 2003
• Glycoprotein IIb/IIIa inhibitors, surgery and bleeding. 29 Sep 1998
• Aspirin resistance or variable response or both? 26 Sep 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.